Abbott Laboratories CEO Robert Ford unpacked his company’s latest quarterly report in a Thursday interview with CNBC’s Jim ...

Abbott Laboratories (ABT) reports robust earnings growth and margin expansion, driven by medical devices, despite headwinds ...

Abbott Laboratories' second-largest division, diagnostics, continues to be a hindrance, while the FY group operating margin ...

Q2 2025 Earnings Call Transcript July 17, 2025 Abbott Laboratories reports earnings inline with expectations. Reported EPS is ...

Shares of Abbott Laboratories (NYSE:ABT) lost ~5% in the premarket on Thursday after the MedTech company provided its ...

Investing.com -- Jefferies upgraded Abbott Laboratories (NYSE: ABT) to Buy from Hold, calling the market reaction to the ...

If you wonder whether Abbott Laboratories (NYSE: ABT) is a good buy in Q2 2025, the answer is yes. The company’s management, portfolio, cash flow, capital return, and pipeline are why. The stock ...

"Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly ...

Second Quarter 2025 Results Key Financial Results Revenue: US$11.1b (up 7.4% from ...

Abbott Laboratories’ Debt totaled $15 Bil at the end of the latest quarter, while its market capitalization stands at $233 ...

Abbott Laboratories has a lower P/E than the aggregate P/E of 53.67 of the Health Care Equipment & Supplies industry. Ideally ...

Abbott Laboratories closed 12.43% short of its 52-week high of $141.23, which the company reached on March 4th.